SKB BIO-B (06990) signed a framework agreement with Colorscience for auxiliary market management services in 2026.

SKB BIO-B (06990) announced that on March 10, 2026, the company entered into a 2026 supplemental market management service framework agreement with Colon Care, under which Colon Care Group will provide the company with auxiliary market management services for the antibody-drug conjugate targeting human trophoblastic cell surface antigen 2 (TROP2) sac-TMT (also known as SKB264/MK-2870) (Jiatai). Colon Care Group provides comprehensive market management services, including but not limited to hospital listing information dissemination, listing customer maintenance, market analysis services, market and competitor information collection, and academic conference support. Colon Care Group is experienced in promoting drugs in China, especially in providing hospital listing information dissemination services. By entering into a 2026 supplemental market management service framework agreement with Colon Care Group, the company will be able to leverage Colon Care Group's existing resources to promote sac-TMT more effectively and achieve listing goals. Furthermore, since Colon Care Group has provided market management services for ustekinumab N01 injection (formerly A140) (brand name: Dataile), the company has established a good working relationship with Colon Care Group. The company believes that Colon Care Group has the industry knowledge required to effectively provide services under the 2026 supplemental market management service framework agreement, and appointing Colon Care Group can avoid the upfront costs associated with appointing a new service provider that has not previously worked with the company.